| Biological Sciences | Lifetime | 519 | US 305 | 99.94 |
| Biological Sciences | 2021-2025 | 120 | US 21 | 99.90 |
| Immunology | Lifetime | 104 | US 65 | 99.81 |
| Molecular Biology | Lifetime | 469 | US 294 | 99.77 |
| Oncology | Lifetime | 160 | US 87 | 99.74 |
| Epidemiology | Lifetime | 284 | US 145 | 99.64 |
| Cancer Research | Lifetime | 618 | US 327 | 95.80 |
| Immunology | 2021-2025 | 6 | US 3 | 99.85 |
| Oncology | 2021-2025 | 65 | US 25 | 99.64 |
| Molecular Biology | 2021-2025 | 267 | US 71 | 98.83 |
| Epidemiology | 2021-2025 | 752 | US 268 | 92.64 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 734 | US 266 | 90.73 |
| Autophagy in Disease and Therapy | Lifetime | 6 | US 3 | 99.94 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 22 | US 13 | 99.94 |
| Cell death mechanisms and regulation | Lifetime | 11 | US 5 | 99.84 |
| Immunotherapy and Immune Responses | Lifetime | 47 | US 34 | 99.90 |
| Mitochondrial Function and Pathology | Lifetime | 83 | US 36 | 99.59 |
| Phagocytosis and Immune Regulation | Lifetime | 14 | US 5 | 99.73 |
| CAR-T cell therapy research | Lifetime | 88 | US 51 | 99.65 |
| Immune Cell Function and Interaction | Lifetime | 217 | US 136 | 99.72 |
| Immune cells in cancer | Lifetime | 73 | US 30 | 99.48 |
| Cancer Research and Treatments | Lifetime | 80 | US 54 | 99.31 |
| interferon and immune responses | Lifetime | 82 | US 45 | 99.29 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 96 | US 56 | 99.08 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 323 | US 158 | 99.04 |
| Cancer-related Molecular Pathways | Lifetime | 212 | US 126 | 99.14 |
| Adenosine and Purinergic Signaling | Lifetime | 126 | US 48 | 97.95 |
| Epigenetics and DNA Methylation | Lifetime | 778 | US 404 | 98.22 |
| Ferroptosis and cancer prognosis | Lifetime | 250 | US 76 | 96.93 |
| PARP inhibition in cancer therapy | Lifetime | 177 | US 91 | 97.50 |
| ATP Synthase and ATPases Research | Lifetime | 295 | US 107 | 96.82 |
| Calcium signaling and nucleotide metabolism | Lifetime | 123 | US 53 | 97.12 |
| Cannabis and Cannabinoid Research | Lifetime | 546 | US 238 | 96.21 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 316 | US 156 | 93.86 |
| Inflammasome and immune disorders | Lifetime | 649 | US 181 | 94.73 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 363 | US 126 | 93.35 |
| Immune Cell Function and Interaction | 2021-2025 | 4 | US 2 | 99.70 |
| Immunotherapy and Immune Responses | 2021-2025 | 4 | US 1 | 99.83 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 32 | US 8 | 99.86 |
| Phagocytosis and Immune Regulation | 2021-2025 | 2 | US 2 | 98.99 |
| interferon and immune responses | 2021-2025 | 26 | US 9 | 97.66 |
| Epigenetics and DNA Methylation | 2021-2025 | 162 | US 55 | 96.75 |
| Immune cells in cancer | 2021-2025 | 170 | US 28 | 96.17 |
| Autophagy in Disease and Therapy | 2021-2025 | 133 | US 20 | 94.86 |
| Ferroptosis and cancer prognosis | 2021-2025 | 289 | US 29 | 95.65 |
| Cell death mechanisms and regulation | 2021-2025 | 21 | US 3 | 93.28 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 46 | US 18 | 91.56 |
| PARP inhibition in cancer therapy | 2021-2025 | 193 | US 73 | 93.55 |
| CAR-T cell therapy research | 2021-2025 | 931 | US 498 | 94.79 |
| Mitochondrial Function and Pathology | 2021-2025 | 523 | US 137 | 90.17 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 272 | US 96 | 88.85 |
| T-cell and B-cell Immunology | 2021-2025 | 627 | US 260 | 88.20 |
| Cancer Research and Treatments | 2021-2025 | 660 | US 181 | 81.98 |
| Cancer-related Molecular Pathways | 2021-2025 | 561 | US 194 | 79.19 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 520 | US 108 | 75.17 |
